---
title: Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
date: '2024-11-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39602653/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241128174911&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Obe-cel resulted in a high incidence of durable response
  among adults with relapsed or refractory B-cell ALL, with a low incidence of grade
  3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics); FELIX
  ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics); FELIX ClinicalTrials.gov number, ...